- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Mediators of Inflammation
Volume 2013 (2013), Article ID 279781, 11 pages
The Endothelial Tyrosine Phosphatase SHP-1 Plays an Important Role for Vascular Haemostasis in TNFα-Induced Inflammation In Vivo
1Medizinische Klinik und Poliklinik IV, Innenstadt, Ludwig Maximilians Universität München, Ziemssenstr. 1, 80336 Munich, Germany
2Walter Brendel Zentrum für Experimentelle Medizin, Ludwig Maximilians Universität München, Marchioninistr. 27, 81377 Munich, Germany
3Frauenklinik und Poliklinik der Technischen Universität München, Technische Universität München, Ismaninger Straße 22, 81675 Munich, Germany
4Invasive Kardiologie, Klinikum Starnberg, Oßwaldstr. 1, 82319 Starnberg, Germany
Received 21 December 2012; Revised 6 March 2013; Accepted 25 March 2013
Academic Editor: Austin Meng Guo
Copyright © 2013 Elisabeth Koch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
- P. Libby, “Inflammation in atherosclerosis,” Nature, vol. 420, no. 6917, pp. 868–874, 2002.
- H. Ohta, H. Wada, T. Niwa et al., “Disruption of tumor necrosis factor-α gene diminishes the development of atherosclerosis in ApoE-deficient mice,” Atherosclerosis, vol. 180, no. 1, pp. 11–17, 2005.
- M. F. Iademarco, J. L. Barks, and D. C. Dean, “Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-α in cultured endothelial cells,” Journal of Clinical Investigation, vol. 95, no. 1, pp. 264–271, 1995.
- H. Zhang, Y. Park, J. Wu et al., “Role of TNF-α in vascular dysfunction,” Clinical Science, vol. 116, no. 3, pp. 219–230, 2009.
- B. L. Goodwin, L. C. Pendleton, M. M. Levy, L. P. Solomonson, and D. C. Eichler, “Tumor necrosis factor-α reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells,” American Journal of Physiology, vol. 293, no. 2, pp. H1115–H1121, 2007.
- X. Gao, S. Belmadani, A. Picchi et al., “Tumor necrosis factor-α induces endothelial dysfunction in Lepr db mice,” Circulation, vol. 115, no. 2, pp. 245–254, 2007.
- A. Picchi, X. Gao, S. Belmadani et al., “Tumor necrosis factor-α induces endothelial dysfunction in the prediabetic metabolic syndrome,” Circulation Research, vol. 99, no. 1, pp. 69–77, 2006.
- A. Kumar, Y. Takada, A. M. Boriek, and B. B. Aggarwal, “Nuclear factor-κB: its role in health and disease,” Journal of Molecular Medicine, vol. 82, no. 7, pp. 434–448, 2004.
- M. S. Wolin, S. A. Gupte, and R. A. Oeckler, “Superoxide in the vascular system,” Journal of Vascular Research, vol. 39, no. 3, pp. 191–207, 2002.
- K. K. Griendling, D. Sorescu, B. Lassègue, and M. Ushio-Fukai, “Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 10, pp. 2175–2183, 2000.
- H. Cai and D. G. Harrison, “Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress,” Circulation Research, vol. 87, no. 10, pp. 840–844, 2000.
- D. D. Wagner and P. C. Burger, “Platelets in inflammation and thrombosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. 2131–2137, 2003.
- G. Davì and C. Patrono, “Mechanisms of disease: platelet activation and atherothrombosis,” New England Journal of Medicine, vol. 357, no. 24, pp. 2482–2494, 2007.
- Y. Huo and K. F. Ley, “Role of platelets in the development of atherosclerosis,” Trends in Cardiovascular Medicine, vol. 14, no. 1, pp. 18–22, 2004.
- C. Weber, “Platelets and chemokines in atherosclerosis: partners in crime,” Circulation Research, vol. 96, no. 6, pp. 612–616, 2005.
- P. S. Frenette, R. C. Johnson, R. O. Hynes, and D. D. Wagner, “Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 16, pp. 7450–7454, 1995.
- G. Li, J. M. Sanders, E. T. Phan, K. Ley, and I. J. Sarembock, “Arterial macrophages and regenerating endothelial cells express P-selectin in atherosclerosis-prone apolipoprotein E-deficient mice,” American Journal of Pathology, vol. 167, no. 6, pp. 1511–1518, 2005.
- P. Libby, “Role of inflammation in atherosclerosis associated with rheumatoid arthritis,” American Journal of Medicine, vol. 121, no. 10, supplement 1, pp. S21–S31, 2008.
- D. H. Solomon, E. W. Karlson, E. B. Rimm et al., “Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis,” Circulation, vol. 107, no. 9, pp. 1303–1307, 2003.
- L. M. Fischer, R. G. Schlienger, C. Matter, H. Jick, and C. R. Meier, “Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction,” American Journal of Cardiology, vol. 93, no. 2, pp. 198–200, 2004.
- I. D. del Rincon, K. Williams, M. P. Stern, G. L. Freeman, and A. Escalante, “High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors,” Arthritis and Rheumatism, vol. 44, no. 12, pp. 2737–2745, 2001.
- H. Yoshida, C. E. Yilmaz, and D. N. Granger, “Role of tumor necrosis factor-alpha in the extraintestinal thrombosis associated with colonic inflammation,” Inflammatory Bowel Diseases, vol. 17, no. 11, pp. 2217–2223, 2011.
- J. Pircher, M. Merkle, M. Wornle et al., “Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2,” Arthritis Research & Therapy, vol. 14, no. 5, p. R225, 2012.
- D. W. McVicar and D. N. Burshtyn, “Intracellular signaling by the killer immunoglobulin-like receptors and Ly49,” Science's STKE, vol. 2001, no. 75, p. RE1, 2001.
- Q. Dong, K. A. Siminovitch, L. Fialkow, T. Fukushima, and G. P. Downey, “Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1,” Journal of Immunology, vol. 162, no. 6, pp. 3220–3230, 1999.
- J. M. Pasquet, L. Quek, S. Pasquet et al., “Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI,” Journal of Biological Chemistry, vol. 275, no. 37, pp. 28526–28531, 2000.
- A. R. Khaled, E. J. Butfiloski, E. S. Sobel, and J. Schiffenbauer, “Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-κB,” Cellular Immunology, vol. 185, no. 1, pp. 49–58, 1998.
- F. Krötz, B. Engelbrecht, M. A. Buerkle et al., “The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation,” Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1700–1706, 2005.
- M. K. Pathak and T. Yi, “Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines,” Journal of Immunology, vol. 167, no. 6, pp. 3391–3397, 2001.
- G. V. R. Born, “Aggregation of blood platelets by adenosine diphosphate and its reversal,” Nature, vol. 194, no. 4832, pp. 927–929, 1962.
- H. Mannell, A. Hammitzsch, R. Mettler, U. Pohl, and F. Krötz, “Suppression of DNA-PKcs enhances FGF-2 dependent human endothelial cell proliferation via negative regulation of Akt,” Cellular Signalling, vol. 22, no. 1, pp. 88–96, 2010.
- H. K. Mannell, J. Pircher, D. I. Chaudhry et al., “ARNO regulates VEGF-dependent tissue responses by stabilizing endothelial VEGFR-2 surface expression,” Cardiovascular Research, vol. 93, no. 1, pp. 111–119, 2012.
- W. Xiao, T. Ando, H. Y. Wang, Y. Kawakami, and T. Kawakami, “Lyn-and PLC-β3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease,” Blood, vol. 116, no. 26, pp. 6003–6013, 2010.
- M. Takano, A. Meneshian, E. Sheikh et al., “Rapid upregulation of endothelial P-selectin expression via reactive oxygen species generation,” American Journal of Physiology, vol. 283, no. 5, pp. H2054–H2061, 2002.
- K. N. Patel, S. H. Soubra, R. V. Bellera et al., “Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, pp. 2225–2230, 2008.
- B. Patel, M. Sharifi, A. D. Milward et al., “Platelet nitric oxide synthase is activated by tyrosine dephosphorylation: possible role for SHP-1 phosphatase,” Journal of Thrombosis and Haemostasis, vol. 4, no. 11, pp. 2423–2432, 2006.
- H. Nakagami, T. X. Cui, M. Iwai et al., “Tumor necrosis factor-α inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 2, pp. 238–242, 2002.
- M. Sugano, Y. Iwasaki, M. Abe, T. Maeda, K. Tsuchida, and N. Makino, “TNF-alpha employs a protein-tyrosine phosphatase to inhibit activation of hepatocyte growth factor receptor and hepatocyte growth factor-induced endothelial cell proliferation,” Molecular and Cellular Biochemistry, vol. 322, no. 1-2, pp. 113–117, 2009.
- R. Pincheira, A. F. Castro, O. N. Ozes, P. S. Idumalla, and D. B. Donner, “Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity,” Journal of Immunology, vol. 181, no. 2, pp. 1288–1298, 2008.
- A. K. Somani, J. S. Bignon, G. B. Mills, K. A. Siminovitch, and D. R. Branch, “Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 21113–21119, 1997.
- R. Siekmeier, C. Steffen, and W. März, “Role of oxidants and antioxidants in atherosclerosis: results of in vitro and in vivo investigations,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 12, no. 4, pp. 265–282, 2007.
- D. Grassi, G. Desideri, and C. Ferri, “Flavonoids: antioxidants against atherosclerosis,” Nutrients, vol. 2, no. 8, pp. 890–902, 2010.
- D. L. Mann, “Targeted anticytokine therapy and the failing heart,” American Journal of Cardiology, vol. 95, no. 11, pp. 9C–16C, 2005.
- M. Sugano, K. Tsuchida, T. Hata, and N. Makino, “RNA interference targeting SHP-1 attenuates myocardial infarction in rats,” FASEB Journal, vol. 19, no. 14, pp. 2054–2056, 2005.
- C. A. Beamer, D. M. Brooks, and D. I. Lurie, “Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia,” Journal of Neuroscience Research, vol. 83, no. 7, pp. 1220–1230, 2006.
- Y.-W. Won, M. Lee, H. A. Kim, D. A. Bull, and S. W. Kim, “Hypoxia-inducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease,” Journal of Controlled Release, vol. 165, no. 1, pp. 22–28, 2013.
- M. Vercauteren, E. Remy, C. Devaux et al., “Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure,” Circulation, vol. 114, no. 23, pp. 2498–2507, 2006.